Patients Derived Organoids in Ovarian Cancer

Recruiting now · Not applicable

Conditions studied: Ovarian Cancer

In brief

Among cancer models, patients derived organoids (PDOs) best reproduce tumor's tissue architecture, intratumor heterogeneity and are able to mimic in vivo patients' drugs response. For these reasons, it has been designed a study to assess the feasibility of PDOs immune cells co-culture in OC patients and the concordance between ex vivo sensitivity and in vivo treatment response. If proven effective and reliable, PDOs could be introduced into clinical practice as empirical predictor of patients' response to antineoplastic drugs.

Key facts

Study ID

NCT06085404

Run by

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

People needed

48

Starts

2021-11-25

Expected to finish

2025-11-25

Last updated by the study team

2025-03-04

Who can join

Age: 18 and older, up to 80. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Preoperative clinical, serological and radiologic suspicion of International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or greater ovarian, fallopian tube, or primary peritoneal cancer;
• Histologic diagnoses of epithelial ovarian cancer at frozen section
• Age >18 and years;
• Estimated life expectancy of at least 4 weeks;
• Performance status (PS) according to Eastern Cooperative Oncology Group (ECOG) < 2

You may not qualify if…

• Non-serous histology at frozen section;
• Patients with a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (> 10 mg equivalent prednisone/daily) or any other form of immunosuppressive therapy within 7 days prior to the enrollment.

Where it is running

• Policlinico Universitario Agostino Gemelli — Roma, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.